This Is AuburnAUrora

Show simple item record

Platelet gene therapy improves hemostatic function for integrin αIIbβ3-deficient dogs

Metadata FieldValueLanguage
dc.contributorMary K. Boudreauxe, boudrmk@auburn.eduen_US
dc.creatorFang, Juan
dc.creatorJensen, Eric S.
dc.creatorBoudreauxe, Mary K.
dc.creatorDu, Lily M.
dc.creatorHawkins, Troy B.
dc.creatorKoukouritaki, Sevasti B.
dc.creatorCornetta, Kenneth
dc.creatorWilcox, David A.
dc.description.abstractActivated blood platelets mediate the primary response to vascular injury. Although molecular abnormalities of platelet proteins occur infrequently, taken collectively, an inherited platelet defect accounts for a bleeding diathesis in ≈1:20,000 individuals. One rare example of a platelet disorder, Glanzmann thrombasthenia (GT), is characterized by life-long morbidity and mortality due to molecular abnormalities in a major platelet adhesion receptor, integrin αIIbβ3. Transfusion therapy is frequently inadequate because patients often generate antibodies to αIIbβ3, leading to immunemediated destruction of healthy platelets. In the most severe cases allogeneic bone marrow transplantation has been used, yet because of the risk of the procedure it has been limited to few patients. Thus, hematopoietic stem cell gene transfer was explored as a strategy to improve platelet function within a canine model for GT. Bleeding complications necessitated the use of a mild pretransplant conditioning regimen; therefore, in vivo drug selection was used to improve engraftment of autologously transplanted cells. Approximately 5,000 αIIbβ3 receptors formed on 10% of platelets. These modest levels allowed platelets to adhere to αIIbβ3’s major ligand (fibrinogen), form aggregates, and mediate retraction of a fibrin clot. Remarkably, improved hemostatic function was evident, with ≤135-fold reduced blood loss, and improved buccal bleeding times decreased to 4 min for up to 5 y after transplant. One of four transplanted dogs developed a significant antibody response to αIIbβ3 that was attenuated effectively with transient immune suppression. These results indicate that gene therapy could become a practical approach for treating inherited platelet defects.en_US
dc.relation.ispartofProceedings of the National Academy of Sciences of the United States of Americaen_US
dc.subjecthematology | recombinant lentivirus-mediated gene transfer | hemostasisen_US
dc.titlePlatelet gene therapy improves hemostatic function for integrin αIIbβ3-deficient dogsen_US
dc.type.genreJournal Article, Academic Journalen_US

Files in this item

This item appears in the following Collection(s)

Show simple item record